• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza virus hemagglutinin stalk-based antibodies and vaccines

tetano

Editor, Senior Moderator
Curr Opin Virol. 2013 Aug 23. pii: S1879-6257(13)00134-X. doi: 10.1016/j.coviro.2013.07.007. [Epub ahead of print]
Influenza virus hemagglutinin stalk-based antibodies and vaccines.
Krammer F, Palese P.
Source

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Florian.Krammer@mssm.edu.
Abstract

Antibodies against the conserved stalk domain of the hemagglutinin are currently being discussed as promising therapeutic tools against influenza virus infections. Because of the conservation of the stalk domain these antibodies are able to broadly neutralize a wide spectrum of influenza virus strains and subtypes. Broadly protective vaccine candidates based on the epitopes of these antibodies, for example, chimeric and headless hemagglutinin structures, are currently under development and show promising results in animals models. These candidates could be developed into universal influenza virus vaccines that protect from infection with drifted seasonal as well as novel pandemic influenza virus strains therefore obviating the need for annual vaccination, and enhancing our pandemic preparedness.

Copyright ? 2013 Elsevier B.V. All rights reserved.

PMID:
23978327
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23978327
 
Back
Top Bottom